IL-33 Treatment Enhances CD103+ Dendritic Cell Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing in vitro cultured dendritic cell therapeutic agents for cancer treatment face challenges in enhancing immunogenicity and inducing effective antitumor immunity, as they often result in side effects and limited therapeutic effects due to immune checkpoint molecules in vivo tumor environments.
Innovation Solution
A method involving the culture of dendritic progenitor cells in a medium with FMS-like tyrosine kinase 3 ligand (Flt3L) and treatment with interleukin-33 (IL-33) during differentiation to induce CD103-positive dendritic cells, which enhances immunogenicity and antitumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GM-CSF or Flt3L is used for in vitro culture of dendritic cells, then dendritic cells can be prepared for tumor therapy, but immunogenicity is insufficient and therapeutic effects are limited
Solution Approach 1:
The patent applies preliminary action by treating dendritic cells with IL-33 during the differentiation stage (days 3-7) rather than after differentiation is complete. This timing allows the cytokine to influence the development of immunogenic properties from the outset, preventing the limitation of insufficient immunogenicity that plagues conventional post-differentiation enhancement methods.
Solution Approach 2:
The patent changes the parameter of differentiation timing by intervening at an intermediate stage (days 3-7) rather than after completion. It also changes the chemical parameter by introducing IL-33 at specific concentrations (1-25 ng/mL) during culture, which transforms the immunogenicity profile of the resulting dendritic cells and enhances therapeutic effectiveness.
2Reliability
If adjuvants or inflammatory cytokines are used to enhance immunogenicity, then immunogenicity increases, but off-target effects and excessive inflammation occur
Solution Approach 1:
The patent uses IL-33 as an intermediary substance that mediates the enhancement of immunogenicity without causing the harmful off-target effects associated with traditional adjuvants and inflammatory cytokines. IL-33 acts as a selective mediator that promotes dendritic cell maturation and antigen-presenting capacity while maintaining safety and avoiding excessive inflammation.
Solution Approach 2:
The patent applies local quality by selectively enhancing immunogenic properties at specific stages of dendritic cell differentiation (days 3-7) rather than applying broad-spectrum inflammatory stimuli. This localized intervention during the differentiation window achieves targeted immunogenicity enhancement without the systemic harmful effects of conventional adjuvants.
3Reliability
If dendritic cells are treated after completion of differentiation, then co-stimulatory molecules increase, but immunogenicity enhancement is insufficient
Solution Approach 1:
The patent implements preliminary action by intervening during the differentiation process (days 3-7) rather than after completion. This timing allows IL-33 to influence the developmental trajectory of dendritic cells, establishing enhanced immunogenic properties during maturation rather than attempting to modify already-differentiated cells, thereby achieving both immunogenicity enhancement and precise differentiation control.
Solution Approach 2:
The patent applies dynamics by treating dendritic cells at a dynamic intermediate stage of differentiation rather than at a static endpoint. The 3-7 day treatment window captures the cells during active transformation, allowing the cytokine to dynamically influence differentiation outcomes and produce dendritic cells with superior immunogenic characteristics.
Data Source
AI summary
The present disclosure relates to a method for increasing anti-tumor immunity of a dendrocytic therapeutic agent and, more specifically, to a method for preparing cluster of differentiation 103 (CD103)-positive dendritic cells, CD103-positive dendritic cells prepared by the preparation method, and a pharmaceutical composition and kit comprising same for cancer immunotherapy, the method comprising a step of treating dendrocyte progenitor cells with interleukin-33 (IL-33) when the dendrocyte progenitor cells are cultured in a medium comprising FMS-like tyrosine kinase 3 ligand (Flt3L) and thus differentiated to dendritic cells. As the dendritic cells differentiated by the preparation method of the present disclosure exhibit a high potential of inducing antigen-specific cytotoxic T cells, compared to control dendritic cells, and antitumor immunity is strongly induced by a subpopulation of the newly differentiated dendritic cells, the preparation method of the present disclosure has the advantage of increasing immunogenicity in the differentiation step in contrast to a convention method of increasing immunogenicity after completion of differentiation to dendritic cells. Therefore, it is expected that novel immune cell therapy capable of greatly increasing a therapeutic effect through the preparation method of the present disclosure and dendritic cells cultured ex vivo using same can be provided.